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Abstract
Recognition of viruses by pattern recognition receptors (PRRs) causes interferon-b (IFN-b) induction, a key event in the anti-
viral innate immune response, and also a target of viral immune evasion. Here the vaccinia virus (VACV) protein C6 is
identified as an inhibitor of PRR-induced IFN-b expression by a functional screen of select VACV open reading frames
expressed individually in mammalian cells. C6 is a member of a family of Bcl-2-like poxvirus proteins, many of which have
been shown to inhibit innate immune signalling pathways. PRRs activate both NF-kB and IFN regulatory factors (IRFs) to
activate the IFN-b promoter induction. Data presented here show that C6 inhibits IRF3 activation and translocation into the
nucleus, but does not inhibit NF-kB activation. C6 inhibits IRF3 and IRF7 activation downstream of the kinases TANK binding
kinase 1 (TBK1) and IkB kinase-e (IKKe), which phosphorylate and activate these IRFs. However, C6 does not inhibit TBK1-
and IKKe-independent IRF7 activation or the induction of promoters by constitutively active forms of IRF3 or IRF7, indicating
that C6 acts at the level of the TBK1/IKKe complex. Consistent with this notion, C6 immunoprecipitated with the TBK1
complex scaffold proteins TANK, SINTBAD and NAP1. C6 is expressed early during infection and is present in both nucleus
and cytoplasm. Mutant viruses in which the C6L gene is deleted, or mutated so that the C6 protein is not expressed,
replicated normally in cell culture but were attenuated in two in vivo models of infection compared to wild type and
revertant controls. Thus C6 contributes to VACV virulence and might do so via the inhibition of PRR-induced activation of
IRF3 and IRF7.
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Introduction
Mammalian cells respond to viral infection by producing pro-
inflammatory cytokines and chemokines and also interferons
(IFNs), of which type I IFNs, consisting of IFN-b and several IFNa
proteins, are particularly important. IFN-a and IFN-b then act in
an autocrine and paracrine manner to switch on hundreds of
target genes which contribute to anti-viral innate immunity by
blocking virus replication and alerting neighbouring cells to the
danger of infection (reviewed in [1]). In addition to their role in
innate immunity, type I IFNs also promote adaptive immune
responses by priming T helper cells and cytotoxic T cells [2]. The
initial production of type I IFNs is due to the activation of IFN
regulatory factors (IRFs), and in particular IRF3, downstream of
pattern recognition receptors (PRRs), which recognize viral DNA,
RNA and proteins. PRRs that detect the presence of foreign RNA
include the RIG-I-like receptors (RLRs) melanoma differentiation-
associated gene 5 (MDA5) and retinoic acid induced gene I (RIG-
I), which sense intracellular double-stranded (ds) RNA and single-
stranded (ss) RNA containing a 59 triphosphate, respectively [3–6].
Other PRRs that aid the detection of viruses include the
endosomal toll-like receptors (TLRs), namely TLR3 which senses
dsRNA, TLR7 and TLR8 which sense ssRNA and TLR9 which
recognizes unmethylated DNA (reviewed in [7]). Intracellular
DNA sensors such as AIM2, RNA polymerase III, DAI and IFI16
are also involved in sensing DNA viruses by recognizing the
presence of dsDNA in the cytosol [8–15]. RNA polymerase III,
DAI and IFI16 signal to cause type I IFN production, while AIM2
activates the inflammasome leading to processing of pro-
interleukin (IL)-1b and release of IL-1b [9,11,12,15]. RNA
polymerase III is unusual in that it does not signal directly in
response to DNA, but instead transcribes AT-rich DNA into RNA
species, which are then recognized by RIG-I [8,10].
The signalling pathways activated by the RLRs, the IFN-
inducing intracellular DNA receptors and by TLR3 converge at
the level of the kinases TNF receptor associated factor (TRAF)
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and IkB kinase-e (IKKe). These kinases exist in complexes with
the scaffold proteins TANK, NAP1 (NAK-associated protein 1) or
SINTBAD (similar to NAP1 TBK1 adaptor) [16–18]. To activate
these kinases, RLRs and consequently RNA polymerase III signal
via the adaptor protein MAVS (mitochondrial antiviral signalling)
[19–21], other intracellular DNA sensors employ STING
(stimulator of IFN genes) [22,23], while TLR3 uses TRIF (TIR-
domain containing adaptor molecule inducing IFN-b) [24,25].
PRRs also require TRAF3 for the activation of TBK1 and IKKe
(reviewed in [26]). Once activated by PRR signalling, TBK1 and
IKKe phosphorylate IRF3, causing its translocation to the nucleus
and the transcriptional activation of promoters containing
appropriate binding sites, such as the IFN-b and CCL5 promoters,
and a subset of promoters containing IFN-stimulated response
elements (ISREs) [27,28]. A related transcription factor of the IRF
family, IRF7, also plays an important role in anti-viral responses
and can be activated in a similar manner to IRF3 during viral
infection [29]. However, while IRF3 is expressed constitutively,
IRF7 is present at low levels in most cells, but is induced by type I
IFNs in a positive feedback loop. Thus, IRF7 is particularly
important for the continued expression of IFN-b during viral
infection, and also contributes to induction of IFN-b by co-
operation with IRF3 [29,30]. In addition, IRF7 is essential for the
induction of IFN-a genes that are not induced by IRF3 [29]. In
plasmacytoid dendritic cells, an alternative TBK1- and IKKe-
independent signalling pathway resulting in the activation of IRF7
is employed by TLR7, TLR8 and TLR9. These endosomal TLRs
signal through the adaptor protein MyD88 (myeloid differentia-
tion factor 88), leading to activation of the kinase IKKa which
then phosphorylates IRF7 [29,31,32]. This is unusual, because in
other PRR signalling pathways IKKa and IKKb are involved in
the phosphorylation of the inhibitor of NF-kB( I kB), causing its
degradation and the subsequent activation of NF-kB. NF-kBi s
another transcription factor activated by PRRs, and is critical for
innate immunity. NF-kB and IRF3 (or IRF7) co-operate with the
activating protein 1 (AP-1) transcription factor family to induce the
transcription of the IFN-b promoter.
A functional type I IFN response provides a potent means of
controlling virus infections [33] and consequently viruses have
evolved numerous counter-measures to stop the production or
action of IFNs or IFN-induced anti-viral proteins (for review see
[34]). These strategies include blockage of antiviral PRR signalling
pathways (reviewed in [34,35]). Viruses with a large DNA genome,
such as poxviruses, encode an extensive array of immunomodu-
latory proteins. Vaccinia virus (VACV), an orthopoxvirus used as a
vaccine to eradicate smallpox, has many immune evasion
mechanisms, and these include intracellular proteins that block
PRR signalling, secreted factors that sequester IFNs and proin-
flammatory cytokines, and proteins that inhibit the effector actions
of an IFN response (reviewed in [36]). However, the exact function
of many of the approximately 200 virus proteins remains unclear.
Here, a functional screen was used to identify VACV proteins that
inhibit the induction of the type I IFN response after PRR
activation. It is shown that protein C6, the product of the C6L
gene, is an inhibitor of IFN-b promoter activation. The C6 protein
is a member of a family of VACV proteins that includes B14, A52
and K7 [37,38]. The crystal structures of B14, A52 and K7 were
solved [39,40] and showed that they, and also VACV proteins N1
[41,42] and F1 [43], adopt a Bcl-2-like fold. Functional
characterisation showed that only F1 and N1 inhibit apoptosis
[42,43] and consistent with this these proteins have a surface
groove for binding BH3 peptides from pro-apoptotic Bcl-2
proteins [42,43]. In contrast, proteins B14, A52 and K7 lack this
groove and inhibit innate immune signalling pathways instead
[40,44]. Interestingly, the protein N1 is both anti-apoptotic and
inhibits NF-kB activation induced by IL-1 [40,42,45].
In this paper we demonstrate that C6 inhibits the activation of
IRF3 and IRF7 downstream of the kinases TBK1 and IKKe,
while C6 does not inhibit signalling pathways using IKKa for
IRF7 activation. Inhibition of IRF3 and IRF7 by C6 may be
mediated by its interaction with the scaffold proteins TANK,
NAP1 and SINTBAD. Consistent with the ability of C6 to inhibit
IFN-b expression, recombinant viruses that do not express C6 are
attenuated in vivo compared to the wild type and revertant viruses.
C6 represents the first viral protein shown to target the TBK1
scaffold proteins.
Results
A screen of VACV proteins identified C6 as an inhibitor of
IFN-b and CCL5 induction
To uncover novel VACV proteins that inhibit innate immune
signalling pathways, a functional screen of proteins from VACV
strain Western Reserve (WR) was used to identify those that inhibit
type I IFN induction. For this, poorly characterized proteins
encoded in the terminal regions of the VACV WR genome were
selected, because these regions are rich in immunomodulatory
proteins [46]. Proteins encoded within the highly conserved
central region of the VACV genome were excluded from the
screen, as were proteins with well-characterized functions, secreted
proteins and those smaller than 8 kDa. This selection process
identified 49 ORFs, and these were amplified from VACV WR
strain genomic DNA, and cloned into mammalian expression
vectors. Plasmids encoding these ORFs were transfected individ-
ually into HEK293 cells, and the effect on the IFN-b promoter
following PRR stimulation was measured by reporter gene assays.
ORF VACVWR022 (gene C6L in VACV Copenhagen strain)
encoding the protein C6 emerged from this screen as an inhibitor
of IFN-b promoter activation. Expression of C6 inhibited the
activation of the IFN-b promoter by transfected poly(dA-dT)
(which acts via intracellular DNA sensors) or poly(I:C) (which acts
via RLRs) in HEK293 cells (Figure 1A, B), and by infection of cells
with Sendai virus which activates RIG-I signalling [4] (Figure 1C).
C6 also inhibited poly(I:C)-induced IFN-b promoter activation in
Author Summary
A key event in the innate immune response to virus
infection is the detection of pathogen-associated molec-
ular patterns (PAMPs) such as viral DNA and RNA by
cellular pattern recognition receptors (PRRs). This leads to
expression of interferon-b (IFN-b) by an infected cell. Many
viruses have evolved mechanisms to evade the induction
of IFN-b. Here a screen of poorly characterized vaccinia
virus (VACV) proteins identified protein C6 as an inhibitor
of IFN-b induction by PRRs. Data presented show that C6
prevents the activation of the transcription factors IRF3
and IRF7 by the kinases TBK1 and IKKe, which are key
components at the point of convergence of several PRR
signalling pathways. C6 interacts with the scaffold proteins
NAP1, TANK and SINTBAD, which are components of the
protein complexes containing TBK1 and IKKe, and this
interaction might modulate the activity of these kinases.
C6 is expressed early during infection and contributes to
virulence because viruses that do not express C6 are
attenuated in two in vivo models compared to wild type
and revertant control viruses.
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C6 inhibited the expression of endogenous IFN-b mRNA in
Sendai virus-infected cells (Figure 1E), as well as the secretion of
the chemokine CCL5 from infected cells (Figure 1F). Thus, the C6
protein significantly reduced the expression of IFN-b and CCL5
after stimulation of PRRs by ligands or viral infection.
C6 does not prevent the activation of NF-kB
During viral infection, IRF3 and NF-kB co-operate to activate
the IFN-b and the CCL5 promoters. IRF3 is phosphorylated by
the kinases TBK1 and IKKe, leading to its dimerization and
translocation to the nucleus. In a similar way, the kinases IKKa
and IKKb phosphorylate IkB, which then releases activated NF-
kB and allows its nuclear accumulation. To investigate whether
the signalling pathways leading to NF-kB or IRF3 activation are
inhibited by C6, the translocation of the NF-kB subunit p65 from
the cytoplasm to the nucleus was measured by confocal
microscopy. For this, HEK293T cells were transfected with a
plasmid expressing GFP-tagged C6, or a control plasmid
expressing GFP for 16 h. The cells were then infected with
Sendai virus for 6 h, or stimulated with IL-1 for 15 min, fixed and
stained for endogenous p65. During Sendai virus infection,
approximately 20% of control cells expressing GFP displayed
p65 accumulation in the nucleus (Figure 2A, B), and the presence
of GFP-tagged C6 did not affect the extent of p65 nuclear
translocation. Furthermore, the expression of C6 did not affect the
nuclear accumulation of p65 in cells stimulated with IL-1, an
activator of NF-kB, which, regardless of whether the cells
expressed GFP or GFP-tagged C6, caused p65 nuclear transloca-
tion in more than 80% of cells (Figure 2A, B).
The effect of C6 on the expression of a luciferase reporter gene
under the control of an NF-kB-dependent promoter was examined
Figure 1. C6 inhibits IFN-b and CCL5 expression. (A–C) HEK293 cells were transfected with an IFN-b-promoter firefly luciferase reporter
plasmid, a renilla luciferase transfection control, and a C6 expression plasmid (C6) or empty vector control (EV). Eight hours after transfection, cells
were stimulated by transfection with 5 mg/ml poly(I:C) (A), or 500 ng/ml poly(dA-dT) (B), with mock-transfected cells (mock) serving as control. In (C)
cells were mock infected (-) or infected with Sendai virus. Firefly luciferase activity was measured 16 h after stimulation and normalized to renilla
luciferase activity. (D) NIH3T3 cells were transfected with an IFN-b-promoter firefly luciferase reporter plasmid, a renilla luciferase transfection control
and a C6 expression plasmid (C6) or empty vector control (EV). Cells were stimulated by transfection with 800 ng poly(I:C) per well, and firefly and
renilla luciferase activities were measured after 24 h. (E, F) HEK293 cells were transfected with empty vector (EV) or C6 expression plasmid (C6), and
stimulated by infection with Sendai virus 24 h after transfection. After a further 24 h, IFN-b mRNA was measured by real-time PCR (E), or CCL5 protein
secretion was measured by ELISA (F). Data are from one representative experiment of at least three, each performed in triplicate. Data are
represented as mean 6 SD. *p,0.05, ** p,0.01 or ***p,0.001 compared to EV.
doi:10.1371/journal.ppat.1002247.g001
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PLoS Pathogens | www.plospathogens.org 3 September 2011 | Volume 7 | Issue 9 | e1002247Figure 2. C6 does not inhibit the translocation or activation of NF-kB. (A) HEK293 cells were grown on coverslips and transfected with
plasmids for the expression of GFP-tagged C6 or GFP as control. Twenty-four hours later, cells were mock treated (mock), infected with Sendai virus
(SeV) for 6 h, or treated with 20 ng/ml IL-1b for 15 min. Cells were fixed and stained for endogenous NF-kB p65 (red). GFP or GFP-C6 are shown in
green, and nuclear DNA is stained with DAPI (blue). (B) Cells expressing GFP or GFP-C6 from (A) were observed by confocal microscopy and scored
for nuclear translocation of p65. At least 100 cells were counted for each sample. Data shown are from one representative experiment of at least
three. (C) HEK293 cells were transfected with a firefly luciferase reporter plasmid under the control of an NF-kB-dependent promoter, a renilla
luciferase transfection control, and a C6 or B14 expression plasmid or empty vector control (EV). Twenty-four hours after transfection cells were
treated with 40 ng/ml TNF-a or 20 ng/ml IL-1b for 8 h. Firefly luciferase activity was normalized to renilla luciferase activity. (D) HEK293 cells were
transfected with TLR3, an NF-kB-dependent firefly luciferase reporter plasmid, a renilla luciferase transfection control, and a C6 or B14 expression
plasmid or empty vector control (EV). Eight hours after transfection cells were treated with 25 mg/ml poly(I:C) for 16 h. Firefly luciferase activity was
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kB-dependent promoter stimulated by IL-1 or tumour necrosis
factor (TNF)-a in HEK293 cells (Figure 2C), or by poly(I:C) in
HEK293 cells expressing TLR3 (Figure 2D). In contrast, the
VACV protein B14, another member of the poxviral Bcl-2-like
protein family, inhibited NF-kB promoter activation under these
conditions (Figure 2C, D) as shown previously [47].
C6 prevents the nuclear translocation of IRF3
The activation and nuclear translocation of IRF3 was investigated
next. HEK293T cells transfected with V5-tagged C6 or V5-tagged
GFP were infected with Sendai virus for 6 h, fixed and stained for
IRF3. In cells infected with Sendai virus, IRF3 translocated to the
nucleus in approximately 30% of cells expressing V5-tagged GFP
(Figure 3A, B). However, in cells expressing V5-tagged C6, the
translocation of IRF3 was impaired, and only 5% of C6-expressing
cells displayed nuclear accumulation of IRF3 (Figure 3A, B). Similar
results were obtained with GFP-tagged C6 (data not shown). This
indicatesthattheinhibitionofpromoterinductionbyC6isduetothe
prevention of the activation and/or nuclear translocation of IRF3,
and not due to an effect on p65 activation.
C6 inhibits IRF3 activation at the level of TBK1 and IKKe
To measure phosphorylation-dependent transactivation activity
of IRF3, a luciferase-based IRF3 transactivation assay was utilized.
This assay uses a fusion protein consisting of the DNA-binding
domain of Gal4 and the transactivation domain of IRF3. When
the IRF3 transactivation domain is phosphorylated by upstream
signalling events, it induces expression of a luciferase reporter gene
under the control of a Gal4-dependent promoter. Using this assay,
C6 inhibited poly(dA-dT)-stimulated IRF3 transactivation
(Figure 3C), providing further evidence that C6 inhibits the
activation of IRF3 by PRRs. To determine which step of the
signalling cascade that leads to IRF3 activation is targeted by C6,
the ectopic expression of signalling proteins that act upstream of
IRF3 activation was used to drive the IRF3 transactivation assay.
The RLR adaptor MAVS and the kinases TBK1 and IKKe all
promoted IRF3 activation in this assay when overexpressed
(Figure 3D, E). Co-expression of C6 inhibited the activation of
IRF3 in a dose-dependent manner in each case (Figure 3D, E),
indicating that C6 acts at the level of these signalling components
or further ‘downstream’ to prevent IRF3 activation.
To gain further mechanistic insight, the ability of C6 to inhibit
the function of IRF3 once it is activated by phosphorylation was
measured. To do this, a constitutively active form of IRF3 (IRF3-
5D) was used in which serine to aspartate mutations mimic the
phosphorylation of five key residues in the IRF3 sequence [48].
Over-expression of IRF3-5D induced the expression of a luciferase
reporter driven by an ISRE element derived from the ISG15
promoter (Figure 3F), which was shown previously to be
transcriptionally activated by IRFs [27]. C6 was unable to prevent
the activation of the ISRE by over-expression of constitutively
active IRF3 (Figure 3F), suggesting that C6 acts to prevent the
activation of IRF3, but is unable to interfere with IRF3 function
once it is activated by phosphorylation.
C6 inhibits the activation of IRF7 by TBK1- and IKKe-
dependent pathways
IRF7 is a transcription factor that is structurally and
functionally related to IRF3 and also participates in the induction
of the IFN-b promoter in response to PRR signalling (reviewed in
[49]). IRF7 can be phosphorylated and activated by two distinct
pathways. TLR3 and cytosolic PRRs, such as sensors of poly(dA-
dT), act via TBK1 and IKKe, while the endosomal TLRs TLR8
and TLR9 activate IRF7 using a signalling pathway independent
of TBK1 and IKKe, but involving MyD88 and IKKa [29,32,50].
The ability of C6 to inhibit the TBK1/IKKe-dependent and -
independent signalling pathways to IRF activation was compared
by employing a luciferase-based IRF7 transactivation assay.
Activation of the TBK1/IKKe-dependent pathway following
infection of HEK293 cells with Sendai virus (outlined in
Figure 4A) was inhibited by C6 (Figure 4B), as was the activation
of IRF7 by the downstream signalling components MAVS, TBK1
and IKKe (Figure 4C, D). To determine whether C6 could inhibit
the TBK1/IKKe-independent pathway to IRF7 activation,
HEK293 cells stably expressing TLR8 were used. Stimulation of
TLR8 by the agonists CL075 or R848 activates IRF7 via MyD88
and IKKa (outlined in Figure 4E), however, this was not inhibited
by C6 (Fig. 4F). Similarly, C6 was unable to inhibit IRF7
activation following over-expression of MyD88 or IKKa
(Figure 4G). As observed for IRF3, C6 was unable to inhibit the
activation of the ISRE element in response to constitutively active
IRF7 (IRF7-4D, Figure 4H).
Taken together, these data indicate that C6 inhibits the
activation of IRF3 and IRF7 by TBK1- and IKKe-dependent
signalling pathways, implying that C6 acts on these kinase
complexes, rather than acting on the transcription factors directly.
C6 function is conserved in monkeypox virus
Published sequence data show that C6 has orthologues in other
orthopoxviruses (OPVs), the capripoxvirus and deerpoxvirus
(www.poxvirus.org), and within the OPV genus the conservation
is high (89–97% amino acid identity). To investigate if C6 function
is also conserved, the ability of the C6 orthologue from
monkeypox virus (MPXV) strain ZAI 1979-005 (92% amino acid
identity) to inhibit poly(dA-dT)-induced IRF3 transactivation was
investigated (Figure S1A). The MPXV ORF encoding the C6
orthologue was amplified from DNA extracted from MPXV-
infected HeLa cells. When a MPXV C6 expression vector was
transfected into cells, the MPXV C6 protein, like the VACV C6
protein, inhibited the pathway at the level of TBK1 and IKKe,
because MPXV C6 inhibited the activation of IRF3 caused by the
over-expression of either of the two kinases, or of the adaptor
protein MAVS (Figure S1B). Thus, the MPXV C6 orthologue
behaved like VACV C6 in the assays tested.
C6 associates with the TBK1 scaffold proteins SINTBAD,
NAP1 and TANK
To investigate how C6 antagonises activation of the pathway at
the level of the TBK1- and IKKe-containing complexes,
interactions between C6 and components of the kinase-containing
complexes were sought by immunoprecipitation. HEK293 cells
were transfected with plasmids encoding FLAG-tagged proteins
and then infected with a VACV expressing HA-tagged C6.
Immunoprecipitation with anti-FLAG antibody co-precipitated
C6 with the scaffold proteins NAP1, SINTBAD and TANK but
not with a FLAG-tagged control protein, FLAG-GFP (Figure 5A).
In contrast, no interaction with TBK1 or IKKe was detected (data
not shown). A reciprocal immunoprecipitation using lysates from
cells over-expressing Streptavidin-tagged C6 and FLAG-tagged
normalized to renilla luciferase activity. Data are represented as mean 6 SD from one representative of at least three experiments each performed in
triplicate. ** p,0.01 or ***p,0.001 compared to EV.
doi:10.1371/journal.ppat.1002247.g002
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PLoS Pathogens | www.plospathogens.org 5 September 2011 | Volume 7 | Issue 9 | e1002247Figure 3. C6 inhibits the nuclear translocation and activation of IRF3. (A) HEK293 cells were grown on glass coverslips and transfected with
plasmids for the expression of V5-tagged C6 or V5-tagged GFP as control. Twenty-four hours after transfection, cells were mock-infected (mock) or
infected with Sendai virus (SeV) for 6 h. Cells were fixed and stained for endogenous IRF3 (red) and V5 (green). Nuclear DNA is stained with DAPI
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adaptors since immunoprecipitation of C6 co-precipitated NAP1,
SINTBAD and TANK, but not GFP (Figure 5B).
It has been proposed that TBK1 and IKKe form distinct
complexes, either as homodimers or heterodimers, which would
contain a specific scaffold protein (namely TANK, NAP1 or
SINTBAD [17,51,52]). To investigate whether the interaction
between C6 and NAP1, TANK or SINTBAD affected the
formation of signalling complexes, the scaffold-kinase interactions
were investigated in the presence or absence of C6. A LUMIER
interaction assay was used, in which a FLAG-tagged scaffold
protein and luciferase-tagged TBK1 were co-expressed in the
presence or absence of C6, and the amount of luciferase co-
immunoprecipitated with the FLAG-tagged allele was quantified
[17,53]. C6 did not prevent the association between TBK1 and
NAP1, SINTBAD or TANK (Figure 5C, E, G). In contrast,
expression of isolated TBK1-binding domains (TBDs) inhibited
the formation of the scaffold-kinase complexes (Figure 5D, F, H) as
described previously [17]. Similar results were obtained for the
interactions between the scaffold proteins and IKKe, which were
(blue). (B) Cells expressing V5–C6 or V5-GFP from (A) were observed by confocal microscopy and scored for nuclear translocation of IRF3. At least 100
cells were counted for each sample. Data shown are from one representative experiment of at least three. (C–E) HEK293 cells were seeded in 96-well
plates, transfected with a pFR-firefly luciferase reporter plasmid under the control of the Gal4 promoter, a renilla luciferase transfection control, and
an IRF3-Gal4 fusion plasmid. C6 expression vector (50, 100 or 150 ng, wedges) and empty vector (EV) were co-transfected per well. Expression
plasmids for signalling factors (50 ng) were included in the transfection where indicated (D and E). In (A), cells were mock-transfected or transfected
with 500 ng/ml poly(dA-dT) 8 h after the initial transfection. Cells were harvested 24 h after the first transfection, and firefly luciferase activity was
measured and normalized to renilla luciferase activity. (F) HEK293 cells were transfected with a firefly luciferase reporter plasmid under the control of
an ISRE element, a renilla luciferase transfection control, and a C6 expression construct or empty vector as above. The ISRE was driven by co-
transfection of 2 ng of IRF3-5D. Cells were harvested 24 h after transfection, and firefly luciferase activity was measured and normalized to renilla
luciferase activity. Data are represented as mean 6 SD from one representative of at least three experiments each performed in triplicate. *p,0.05,
** p,0.01 or ***p,0.001 compared to EV.
doi:10.1371/journal.ppat.1002247.g003
Figure 4. C6 prevents IRF7 transactivation stimulated by TBK1-and IKKe-dependent pathways. (A,E) Schematic outline of a TBK1/IKKe-
dependent (A) and –independent (E) pathway resulting in the activation of IRF7. (B–D, F, G) HEK293 cells were transfected with pFR-firefly luciferase
under the control of the Gal4 promoter, a renilla luciferase transfection control, and an IRF7-Gal4 fusion plasmid. C6 expression vector and empty
vector (EV) were co-transfected as indicated. In (B), cells were infected with Sendai virus (SeV) for 16 h. (C, D, G) Expression plasmids (50 ng) for
signalling factors were included in the initial transfection as indicated. (F) HEK293 cells expressing TLR8 were stimulated with 2.5 mg/ml CL075 or
1 mM R848 for 16 h. (H) HEK293 cells were transfected with a firefly luciferase reporter plasmid under the control of an ISRE element, a renilla
luciferase transfection control, and a C6 expression plasmid or empty vector. The ISRE was driven by co-transfection of 2 ng of IRF7-4D. In all cases,
cells were harvested 24 h after the first transfection, Firefly luciferase activity was measured and normalized to renilla luciferase activity. Data are
represented as mean 6 SD from one representative of three experiments, each performed in triplicate. ** p,0.01 or ***p,0.001 compared to EV.
doi:10.1371/journal.ppat.1002247.g004
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PLoS Pathogens | www.plospathogens.org 7 September 2011 | Volume 7 | Issue 9 | e1002247Figure 5. C6 interacts with NAP1, TANK and SINTBAD. (A) HEK293 cells were grown in 10-cm dishes and transfected with 10 mg plasmids
encoding FLAG-tagged NAP1, SINTBAD, TANK or GFP as indicated. After 48 h, cells were infected with recombinant VACV expressing HA-tagged C6 (2
p.f.u. per cell) for 16 h. Cell lysates (input) were subjected to immunoprecipitation (IP) with anti-FLAG M2 agarose beads. Proteins were separated by
SDS-PAGE and detected by immunoblotting as indicated on the right. (B) HEK293 cells were grown in 10-cm dishes and transfected with 5 mg
plasmids encoding FLAG-tagged NAP1, SINTBAD, TANK or GFP and 5 mg TAP-tagged (consisting of FLAG and Strep epitopes) C6 as indicated. After
48 h cell lysates (input) were subjected to immunoprecipitation (IP) with Streptavidin agarose beads. Proteins were separated by SDS-PAGE and
detected by immunoblotting as indicated on the right. (C–H) HEK293 cells were grown in 6-well plates and transfected with 0.5 mg luciferase-tagged
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associate with the scaffold proteins TANK, NAP1 and SINTBAD,
without disrupting the formation of the signalling complexes
containing the kinases TBK1 or IKKe.
C6 is expressed early during infection by VACV and
localises to both the cytoplasm and nucleus
The expression of C6 protein during infection was investigated
by infecting BSC-1 cells with VACV WR in the presence or
absence of cytosine arabinoside (AraC), an inhibitor of viral DNA
replication and hence intermediate and late protein expression.
Using a polyclonal antiserum raised against C6 protein expressed
in Escherichia coli, a 17-kDa C6 protein was detected starting from
2 h post infection, with continued expression at all time points
thereafter (Figure 6A). Also, C6 was detected in the presence of
AraC confirming its expression prior to DNA replication and
hence as an early protein during infection, consistent with previous
data for C6L mRNA expression [54]. In contrast, the expression of
the late protein D8 [55] was blocked by the presence of AraC.
To characterize the contribution of the C6 protein to VACV
replication, spread and virulence, recombinant viruses that did or
did not express the C6 protein were generated. These viruses
included a C6L deletion virus (vDC6) lacking the C6 ORF, a
plaque purified wild type virus (vC6WR) that was isolated from the
same intermediate virus as the deletion mutant during transient
dominant selection (see methods), a revertant virus where the C6L
ORF was re-inserted into the deletion virus at its natural locus
(vC6Rev), and an additional recombinant virus (vC6FS) where the
C6 translational initiation codon was disrupted by the insertion of
an adenine nucleotide. As expected, this virus, as well as vDC6, did
not express C6 protein whereas vC6WR and vC6Rev both did
(Figure 6B). For localisation and interaction studies a virus
expressing HA-tagged C6 was constructed (vC6HA). Reduced
levels of C6 were detected from this recombinant virus using the
TBK1 expression plasmid, 0.5 mg FLAG-tag expression plasmid and 3 mg C6 or TBD expression vector or empty vector (EV) as indicated. Cells were
harvested after 24 h and subjected to immunoprecipitation with anti-FLAG antibody. Immunoprecipitated protein complexes were eluted with FLAG
peptide and co-immunoprecipitated luciferase activity was measured. Data are representative of at least three experiments.
doi:10.1371/journal.ppat.1002247.g005
Figure 6. C6 is expressed early during infection and is present in both the cytoplasm and nucleus. (A) BSC-1 cells were infected with
VACV (5 p.f.u. per cell) in the presence or absence of cytosine arabinoside (AraC) and harvested at the indicated times post infection. Protein extracts
were separated by SDS-PAGE and analysed by immunoblotting with the antibodies indicated. Molecular mass markers are indicated on the right
(kDa). (B) Purified recombinant VACVs were used to infect BSC-1 cells overnight with 5 p.f.u. per cell. Protein extracts were separated by SDS-PAGE
and analysed by immunoblotting with the antibodies indicated. (C) HeLa cells were infected for 16 h with 5 p.f.u. per cell. Cells were harvested and
fractionated into cytoplasmic and nuclear fractions. Proteins from cell extracts were separated by SDS-PAGE and analysed by immunoblotting with
the indicated antibodies. Three-fold more of the total nuclear fraction was loaded compared to the total cytoplasmic fraction. (D) HeLa cells were
infected with the indicated viruses for 5 h with 5 p.f.u. per cell. Cells were then fixed and stained with a mouse anti-HA antibody. The localisation of
C6 (green), nuclear and viral DNA stained with DAPI (blue), phase-contrast and merged images are shown.
doi:10.1371/journal.ppat.1002247.g006
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compared to wild-type C6 or poorer detection by the antiserum.
Nevertheless this protein was detected using an antibody against
the HA epitope (Figure 6B), and shown to be functional in that it
was capable of inhibiting IFN-b promoter induction when
expressed from a plasmid (data not shown).
The intracellular localisation of C6 was investigated by
biochemical fractionation of cells into cytoplasmic and nuclear
fractions, followed by immunoblotting using the anti-C6 serum
(Figure 6C). The integrity of nuclear and cytoplasmic fractions was
confirmed by blotting for lamin A and C, and for tubulin,
respectively. The expression of C6 was detected in both nuclear
and cytoplasmic fractions of cells infected with the wild-type virus
expressing C6 (vC6WR), the revertant virus (vC6Rev) or the virus
expressing HA-tagged C6 (vC6HA) (Figure 6C). The anti-C6
serum was not suitable for the detection of wild-type C6 by
immunofluorescence. However, both nuclear and cytoplasmic
localisation of C6 was also observed by confocal microscopy when
cells infected with vC6HA were stained with an antibody against
the HA tag (Figure 6D).
C6 is not required for replication in cell culture
The isolation of the deletion mutant and vC6FS virus indicated
that C6 is not essential for VACV replication. To determine
whether loss of C6 had an effect on virus replication kinetics or
spread, the plaque size and virus growth in cell culture were
analysed. The size of the plaques formed 72 h post infection with
the various recombinant viruses was measured in three different
cell lines: African green monkey BSC-1 cells, rabbit RK-13 cells
and human TK-143 cells. The absence of C6 had no effect on the
mean plaque size in any of the cell types studied (Figure S3A). To
assess viral replication, BSC-1 cells were infected at a high (10) or
low (0.01) multiplicity of infection (m. o. i.) with the set of
recombinant viruses, and virus in the intracellular and extracel-
lular fractions at various time points post infection was titrated by
plaque assay (Figure S3B–E). No significant difference was
observed between the titres of either the extracellular or
intracellular forms of the recombinant viruses.
C6 is a VACV virulence factor
The contribution of C6 to VACV virulence was tested in two
murine models of infection. In the intranasal (i.n.) model, groups of
10 BALB/c mice were infected with the recombinant viruses at
5610
3 plaque forming units (p.f.u.) per animal and weight loss and
signs of illness were recorded and compared. A significant
difference in weight loss was observed between the viruses that
did not express C6 (vDC6 and vC6FS) and those that did express
C6 (vC6WR and vC6Rev) between days 6 and 12 post infection
(Figure 7A), with the mice infected with the C6 deletion viruses
losing less weight overall and gaining weight more quickly during
recovery. The viruses lacking C6 also caused significantly fewer
signs of illness in infected mice between day 5 and day 12 after
infection (Figure 7B).
In addition, the recombinant viruses were used to infect groups
of 10 BL/6 mice intradermally with 10
4 p.f.u. virus per ear, in
both ears, and the sizes of the resulting lesions were measured and
compared. The lesions induced by vDC6 and vC6FS were
significantly smaller than those induced by vC6WR and vC6Rev
between 6 and 26 days post infection (Figure 7C). In addition the
lesions induced by the viruses lacking C6 began to heal sooner (11
days post infection) than those induced by the viruses that did
express C6 (14 days post infection) (Figure 7C). Thus, these data
show that a virus lacking C6 is attenuated in vivo and indicate C6 is
a virulence factor in two different models of infection.
Discussion
Here the VACV protein C6 is described as a novel modulator of
the innate immune system. Data presented show that C6 inhibits
IFN-b expression by preventing the activation of the transcription
factors IRF3 and IRF7, while not affecting NF-kB activation. C6
acts at the level of the kinases TBK1 and IKKe, and is able to
associate with the kinase-associated scaffold proteins NAP1,
TANK and SINTBAD. The immunomodulatory function of C6
is likely to be important during infection, as a deletion virus lacking
C6 is attenuated in mouse models in vivo.
C6 was identified as an inhibitor of the initiation of the IFN-b
response in a screen of poorly characterised VACV proteins. That
C6 might be an immunomodulator had been suggested by the
previous observations that it belongs to a family of poxvirus
proteins [37] whose members (A46, A52, B14, N1 and K7) were
shown subsequently to belong to the Bcl-2 protein family and to
have immunomodulatory activity (reviewed in [38]). While the
family members share structural similarity, their degree of amino
acid similarity is low indicating they diverged long ago and
although they share an ability to manipulate innate immune
signalling pathways, they differ in their targets and mechanisms of
action. While A46 acts at the interface between TLRs and their
adaptors [56], A52 targets the more downstream signalling factors
TRAF6 and IL-1 receptor associated kinase 2 (IRAK2) [57]. B14,
K7 and now C6 all appear to target the kinase complexes located
at the point of convergence between several different PRR
signalling pathways. However, each of the viral proteins targets
distinct components of these complexes. B14 binds IKKb and
thereby inhibits IkB phosphorylation and NF-kB activation [47].
In contrast, K7 inhibits IRF3 phosphorylation by binding to the
helicase DDX3, which is part of the complexes containing TBK1
and IKKe [58].
In this paper C6 is shown to inhibit the activation of IRF3 and
IRF7 in a different way to K7, namely by interacting with TANK,
NAP1 and SINTBAD. These three proteins act as scaffold proteins
that associate constitutively with TBK1 and IKKe [17,59,60]. They
are essential for the innate immune response to several different
viruses and PAMPs, and in particular for the activation of IRFs, but
notNF-kB,uponstimulationwithSendaivirusorpoly(I:C)[16–18].
The observation that the scaffold proteins are targeted by a viral
immunomodulator provides additional evidence for the importance
of these proteins in the antiviral response. The precise function of
TANK, NAP1 and SINTBAD in the process of TBK1 and IKKe
activation has not been defined fully, but there is evidence that the
adaptor proteins link the kinases to the upstream signalling
pathways, possibly by interaction with TRAF3, which is a
component of TLR and RLR signalling pathways [16]. The
recruitment of the kinase complexes to TRAF3 would then require
the scaffold proteins, and lead to the phosphorylation and activation
of TBK1 and IKKe, ultimately leading to the phosphorylation of
IRF3 and IRF7. However, how exactly complex formation is linked
to the activation of the kinases, and which functions of the adaptors
may be redundant or unique, has yet to be elucidated.
NAP1, TANK and SINTBAD are related in domain structure,
possessing N-terminal coiled-coil regions that are important for
homodimerization, and a central TBD, which mediates the
interaction with TBK1 and IKKe [17]. While C6 interacted with
all three scaffold proteins, it did not affect their interaction with
either TBK1 or IKKe. In contrast, truncated proteins containing
only the TBD of either NAP1, TANK or SINTBAD inhibited all
the scaffold-kinase interactions in this assay, as described
previously [17]. Thus the exact mechanism whereby C6 disrupts
IRF activation remains to be determined. It is possible that C6
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PLoS Pathogens | www.plospathogens.org 10 September 2011 | Volume 7 | Issue 9 | e1002247Figure 7. VACV lacking C6 is attenuated in vivo. (A, B) Virulence in a murine intranasal model of VACV infection. Female BALB/c mice (n=10)
were infected with 5610
3 p.f.u. of the indicated viruses and their weights (A) and signs of illness (B) were monitored daily. Weight data (B) are
expressed as the percentage 6 SEM of the mean weight of the same group of animals on day 0. Signs of illness data (B) are expressed as the mean
score 6 SEM. The horizontal bar indicates the days on which the weight loss or signs of illness induced by vDC6 and vC6FS were statistically different
Vaccinia Virus Virulence Factor C6 Inhibits IRF3
PLoS Pathogens | www.plospathogens.org 11 September 2011 | Volume 7 | Issue 9 | e1002247prevents the association of the scaffold-kinase complexes with
TRAF3, or else prevents the activation of TBK1 and IKKe once
the complexes are formed. Also, it is possible that the interaction
between C6 and the scaffold proteins is indirect and is mediated by
additional proteins that may be part of the kinase signalling
complexes. Further analysis of the effect of C6 on these protein
complexes may shed some light on the mechanism by which
TBK1 and IKKe are activated - and inhibited - during viral
infection.
VACV is not the only virus that inhibits the TRAF3-scaffold-
kinase axis. Recently it was shown that the M protein of severe
acute respiratory syndrome (SARS) coronavirus targets a complex
containing TRAF3, and prevents the association of TRAF3 with
TBK1, IKKe or TANK [61]. Like C6, the M protein inhibits the
induction of the IFN-b promoter by inhibiting IRF3 activation
[61]. However to our knowledge C6 is the first viral protein shown
to associate with all three scaffold proteins.
VACV expresses several proteins that inhibit IRF activation,
including the related Bcl-2-like protein K7, which also targets a
TBK1-containing protein complex [58]. However, despite this, the
effectsofK7and C6areevidentlynotduplicative,becausewhenK7
is still expressed, loss of C6causeda markedvirus attenuationintwo
models of infection. Similarly, there are several VACV proteins that
inhibit NF-kB activation, for instance A52, A46, N1, B14. Yet
deletion of any single member of this group causes virus attenuation
suggesting non-redundant functions. Possible explanations for this
non-redundancy might be cross talk between different pathways, so
the outcome of blocking a pathway is influenced by the point at
which a virus inhibitor functions to block the pathway. Alterna-
tively, the virus proteins might have multiple functions as has been
demonstrated for VACV protein N1. The need for the virus to
express so many different non-redundant viral inhibitors of host
signalling cascades may be due to the host innate immune system
being able to partially compensate for the inhibition of an individual
signalling component by using parallel pathways all ultimately
leading to the induction of type I IFNs and pro-inflammatory
cytokines. Furthermore, the importance of one particular signalling
pathway or component may vary depending on the cell type
infected or stage of infection,thus requiringthe inhibitionof several,
seemingly redundant signalling proteins. Finally, it is plausible that
the inhibition exerted by a single viral protein in not complete,
particularly at early stages of infection, thus requiringthe expression
of several different factors targeting components of the same
pathway to have an additive effect.
The characterization of poxvirus proteins that inhibit the innate
immune system is of interest, since elucidating the mechanism of
viral inhibition often reveals new insights into how innate
immunity operates. Furthermore, VACV strains are in develop-
ment as vaccine delivery systems against smallpox and other
pathogens (reviewed in [62]), and as vectors for the targeting of
tumours and for gene therapy (reviewed in [63]). It is shown here
that deletion of a single ORF can attenuate the virus, thus possibly
making it safer for clinical use. Also, the deletion of ORFs that
encode inhibitors of the innate immune system would be predicted
to make the virus more immunogenic, and thus make a more
effective vaccine. In this context, it is interesting to note that C6 is
conserved in most OPVs and that the MPXV orthologue of C6 is
functionally equivalent to the C6 protein from VACV strains WR.
Materials and Methods
Plasmids
For the screen of VACV candidate immunomodulators, 49
ORFs were selected from the VACV WR strain genome and
amplified by PCR from VACV WR genomic DNA isolated by
phenol-chloroform extraction from purified viral cores. Candidate
ORFs including C6L and B14R were cloned into the expression
vector pCMV-HA (Clontech). C6 was also subcloned into
pLENTI-Dest-V5 (Invitrogen) for immunoflourescence experi-
ments. The ORF encoding MPXV C6 was amplified by PCR
from DNA extracted from MPXV-infected HeLa cells (a kind gift
from K. Rubins, Whitehead Institute) and cloned into pCMV-HA
(Clontech). IFN-b-promoter luciferase reporter was a gift from T.
Taniguchi (University of Tokyo, Japan) and NF-kB luciferase was
from R. Hofmeister (University of Regensburg, Germany). ISRE-
Luciferase and pFR-Luciferase were purchased from Promega.
GL3-Renilla vector was made by replacing the firefly luciferase
ORF from pGL3-control (Promega) with the renilla luciferase
ORF from pRL-TK (Promega). FLAG- and luciferase fusions with
signalling proteins for the LUMIER assay were described in [17].
IKKa was from Tularik Inc. Vectors expressing IRF3-Gal4,
IRF7-Gal4, TBK1, IKKe and TRIF were a kind gift from K.A.
Fitzgerald (University of Massachusetts Medical School, USA),
MAVS was from T.J. Chen (University of Texas Southwestern
Medical Centre, USA), MyD88 was from M Muzio (Milan, Italy),
TLR3 was from D. T. Golenbock (University of Massachusetts
Medical School, USA), and IRF3-5D and IRF7-4D were from J.
Hiscott (McGill University, Montreal, Canada).
For construction of the C6 deletion virus 250-bp flanking
regions of the C6L gene were amplified by PCR from VACV WR
genomic DNA, ligated together and inserted into a plasmid
containing the Escherichia coli guanylphosphoribosyl transferase (Ecogpt)
gene fused in-frame with the enhanced green fluorescent protein (EGFP)
gene (Z11DC6). For construction of Z11C6rev, Z11C6FS and
Z11C6HA, C6L, C6L with an additional adenine nucleotide in the
start codon or C6L with a C-terminal HA tag respectively, plus
C6L flanking regions were amplified from VACV WR genomic
DNA and inserted into the Z11 plasmid.
Antibodies and reagents
C6 polyclonal antiserum was raised against C6 protein purified
from Escherichia coli and injected into rabbits (Eurogentec). Other
antibodies were from the following sources: IRF3 (IBL), V5 (Cell
Signaling), p65 (Santa Cruz), IgG from rabbit serum (Sigma),
TBK1 (Cell Signaling), IKKe (Abcam), TANK (Abcam), FLAG
(Sigma), Lamins A+C (Abcam), tubulin (Upstate Biotech). The
mouse monoclonal antibody AB1.1 against D8 has been described
previously [64]. Poly(I:C) and poly(dA-dT) were from Sigma,
TNF, IL-1, CLO75 and R848 were from Invivogen.
Cells
HEK293 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM, GIBCO) supplemented with 10% fetal bovine
serum (FBS, Biosera) and 10 mg/ml ciprofloxacin (Sigma). BSC-1
cells were maintained in DMEM supplemented with 10% FBS
and penicillin/streptomycin (P/S) (50 mg/ml). RK-13 and TK
-143
cells were maintained in minimum essential medium (MEM)
(P,0.05) from both vC6WR and vC6Rev. (C) Virulence in murine intradermal model of VACV infection. Female C57BL/6 mice (n=10) were infected
with 10
4 p.f.u. of the indicated viruses in both ears and the resulting lesions were measured daily. Data are expressed as the mean lesion size 6 SEM.
The horizontal bar indicates the days on which the lesion size caused by vDC6 and vC6FS were statistically different (P,0.05) from both vC6WR and
vC6Rev.
doi:10.1371/journal.ppat.1002247.g007
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were maintained in DMEM supplemented with 10% newborn
bovine serum (NBS) and P/S (50 mg/ml). HeLa cells were
maintained in MEM supplemented with 10% FBS, 1:100 non-
essential amino acids (NEAA) (Sigma) and P/S (50 mg/ml).
Construction of recombinant viruses
C6 recombinant viruses were constructed using the transient
dominant selection method [65]. For construction of vDC6, RK-
13 cells were infected with VACV strain WR at 0.01 p.f.u. per cell
and then transfected with the Z11DC6 plasmid using polyethy-
lenimine (PEI) (1 mg/ml) according to the manufacturer’s
instructions. Progeny virus was harvested after 48 h and used to
infect RK-13 cells in the presence of mycophenolic acid (MPA,
25 mg/ml), hypoxanthine (HX, 15 mg/ml) and xanthine (X,
250 mg/ml). EGFP-positive plaques were selected and purified
by three rounds of infection using RK-13 cells in the presence of
MPA, HX and X as above. Intermediate virus was resolved in
BSC-1 cells by three rounds of infection in the absence of MPA,
HX and X. The genotype of resolved viruses was analysed by
PCR following proteinase K-treatment of infected RK-13 cells.
Revertant viruses were constructed in a similar manner by
transfection of plasmid Z11C6rev (for vC6 rev), Z11C6FS (for
vC6FS) or Z11C6HA (for vC6HA) into vDC6 infected cells.
Reporter gene assays
Luciferase reporter gene assays were performed in HEK293
cells seeded in 96-well plates and transfected with 0.8 ml Genejuice
(Merck) per well. Firefly reporter plasmid (60 ng), 20 ng GL3-
Renilla control plasmid and 150 ng expression vector or empty
vector control were used per well. For the IRF3 and IRF7 reporter
gene assays, 60 ng pFR-Luciferase and 20 ng pGL3-Renilla were
transfected together with 4 ng of IRF3-Gal4 or IRF7-Gal4, and
150 ng expression vector or control plasmid. For luciferase assays
in NIH3T3 cells, cells were seeded in 96-well plates and
transfected with 60 ng IFN-b-luciferase, 10 ng pRL-TK, and
250 ng expression vector or empty vector control. Cells were lysed
in Passive Lysis Buffer (Promega), and firefly luciferase activity was
normalized to renilla luciferase activity. Experiments were
performed in triplicate and repeated at least 3 times.
Real-time PCR
RNA from HEK293 cells grown in 12-well plates was extracted
using the RNeasy kit (QIAGEN), and converted to cDNA using
the Quantitect RT kit (QIAGEN). IFN-b mRNA was quantified
by real-time PCR with the TaqMan gene expression assay
Hs00277188_s1 and a b-actin endogenous control VIC-MGB
probe (6-carboxyrhodamine–minor groove binder; Applied Bio-
systems). Experiments were performed in triplicate.
ELISA
Cell culture supernatants from HEK293 cells grown in 96-well
plates were assayed for CCL5 protein using Duoset reagents (R&D
Biosystems).
Confocal microscopy
HEK293 cells were grown on glass coverslips and fixed with 4%
paraformaldehyde in PBS. Cells were permeabilized in 0.5%
Triton in PBS, pre-incubated for 1 h in blocking buffer (5% BSA,
0.05% Tween-20 in PBS), stained for 3 h with primary antibody
(1:300 in blocking buffer) and for 1 h with Alexa488 or Alexa647-
labelled secondary antibodies (1:500, Invitrogen). Coverslips were
mounted in MOWIOL 4-88 (Calbiochem) containing DAPI (4,6-
diamidino-2-phenylindole; 1 mg/ml). Images were taken on an
Olympus FV1000 scanning confocal microscope.
Co-immunoprecipitation and LUMIER assay
For co-immunoprecipitation, HEK293T cells were grown in
10-cm dishes and co-transfected with vectors expressing FLAG-
tagged proteins and a vector expressing TAP-tagged (consisting of
FLAG and Streptavidin epitopes) C6, using Fugene-6 (Roche), or
transfected with the vectors expressing FLAG-tagged proteins
alone and then infected 48 h later with vC6HA (2 p.f.u. per cell)
for 16 h. Cells were lysed in lysis buffer (0.1 (v/v) % Triton X-100,
150 mM NaCl, 10% glycerol, 10 mM CaCl2, 20 mM Tris-HCl
pH 7.4 and protease inhibitors), pre-cleared by centrifugation and
incubated with 30 ml of anti-FLAG M2 agarose beads (Sigma), or
strepavidin agarose beads (Thermofisher) for 3 h. Immunoprecip-
itates were washed 3 times in lysis buffer, and eluted from the
beads by boiling in sample buffer containing SDS. Proteins were
resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and
detected by immunoblotting.
For the LUMIER assay, HEK293 cells were grown in 6-well
plates and transfected with 0.5 mg FLAG-tagged plasmid, 0.5 mg
luciferase-tagged plasmid and 3 mg C6 expression vector, TBD
expression vector or empty vector control using GeneJuice
(Merck). Cells were harvested 24 h later in Passive Lysis Buffer
(Promega), and subjected to immunoprecipitation using 0.3 ml
FLAG antibody pre-coupled to Protein A sepharose beads.
Immunoprecipitates were washed 5 times in lysis buffer and
eluted using 100 mM FLAG peptide (Sigma) in PBS, and renilla
luciferase activity was measured.
Cellular fractionation
HeLa cells were infected with recombinant VACVs at 5 p.f.u.
per cell for 16 h. The cells were washed twice in ice-cold LS buffer
(20 mM Hepes pH 7.8, 0.5 mM DTT, 0.5 mM MgCl2 in water)
and allowed to swell on ice for 20 min. The cells were gently
scraped and disrupted by Dounce homogenisation on ice. The
lysates were centrifuged at 6006g for 2 min at 4uC to pellet the
nuclei. The supernatant (cytoplasmic fraction) was removed. The
nuclei were washed five times in PBS, placed in nuclei
resuspension buffer (50 mM Tris-HCl pH 8, 0.5 mM MgCl2,
20 mM iodoactetamide supplemented with protease inhibitor
(Roche)) and sonicated. Proteins were resolved by SDS-PAGE and
detected by immunoblotting.
In vitro growth curves
For the single-step growth curves BSC-1 cells were infected with
10 p.f.u. per cell. At 0 h, 12 h and 24 h post infection the medium
was removed and the cells were collected by centrifugation at
5006 g for 10 min. The supernatant was removed and
extracellular virus titres were determined by plaque assay on
BSC-1 cells. For intracellular virus, cells were scraped, collected by
centrifugation and subjected to three rounds of freeze-thawing
before determining viral titre by plaque assay. For the multi-step
growth curve BSC-1 cells were infected with 0.01 p.f.u. per cell
and intracellular and extracellular virus was harvested at 0, 12, 48
and 72 h post infection as described above.
Plaque size assay
RK-13, BSC-1 and TK-143 cell monolayers were infected in
duplicate with virus at 50 p.f.u. per well for 72 h to allow
formation of well separated plaques. The cells were washed once
with PBS and stained for 30 min with crystal violet (5% (v/v)
crystal violet solution (Sigma), 25% (v/v) ethanol). Wells were then
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measured using Axiovision 4.6 software and a Zeiss Axiovert
200 M microscope.
Murine intranasal and intradermal models of infection
Female BALB/c mice (n=10, 6–8 weeks old) were infected
intranasally (i.n.) with 5610
3 p.f.u. and monitored as described
previously [66,67]. Female C57BL/6 mice (n=10, 6–8 weeks old)
were inoculated intradermally (i.d.) in the ear pinnae with 10
4
p.f.u. as described previously [68,69].
Statistical analysis
Data were analysed using Unpaired Student’s T tests. Statistical
significance is expressed as follows: * P,0.05, ** P,0.01, ***
P,0.001.
Accession numbers
VACV WR C6, P17362.1; TBK1, AF191838_1; IKKe,
NP_054721; NAP1, AAO05967; TANK, NP_001186064; SINT-
BAD, NP_055541; IKKa, NP_001269; MyD88, AAC50954;
MAVS, Q7Z434.2; IRF3, AAH09395; IRF7, NP_001563; NF-kB
p65, CAA80524; IFN-b, NC_000009.11; CCL5, NC_000017.10.
Supporting Information
Figure S1 C6 function is conserved in monkeypox virus.
(A, B) HEK293 cells were seeded in 96-well plates, transfected
with a pFR-firefly luciferase reporter plasmid under the control of
the Gal4 promoter, a renilla luciferase transfection control, and an
IRF3-Gal4 fusion construct. C6 expression vector (50, 100 or
150 ng, wedges) and empty vector (EV) were co-transfected per
well. In (A), cells were mock transfected or transfected with
500 ng/ml poly(dA-dT) 8 h after the initial transfection. In (B),
50 ng plasmids expressing the indicated signalling protein were
included in the initial transfection. Cells were harvested 24 h after
the first transfection, firefly luciferase activity was measured and
normalized to renilla luciferase activity. *p,0.05, ** p,0.01 or
***p,0.001 compared to EV.
(TIF)
Figure S2 C6 does not prevent the interaction between
scaffold proteins and IKKe. (A–C) HEK293 cells were grown
in 6-well plates and transfected with 0.5 mg luciferase-tagged IKKe
expression construct, 0.5 mg FLAG-tag expression construct and
3 mg C6 expression vector or empty vector (EV) as indicated. Cells
were harvested after 24 h and subjected to immunoprecipitation
with anti-FLAG antibody. Immunoprecipitated protein complexes
were eluted with FLAG peptide and co-immunoprecipitated
luciferase activity was measured. Data is representative of at least
three experiments.
(TIF)
Figure S3 C6 deletion does not affect viral replication or
spread in tissue culture. (A) Monolayers of BSC-1, RK-13
and TK-143 cells were infected with the indicated viruses for 72 h.
Cells were stained with crystal violet and the plaque size was
measured using Axiovision 4.6 software and a Zeiss Axiovert
200 M microscope. Results are expressed as the mean plaque
radius 6 SD. (B–E) For construction of single- (B, C) and multi-
step (D, E) growth curves, BSC-1 cells were infected in duplicate
at the p.f.u. per cell indicated for 90 min. Unbound virus was
washed off, cells were harvested at the indicated time points, and
intracellular (B, D) and extracellular (C, E) virus components
were separated. Virus infectivity was titrated by plaque assay on
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